Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T00:07:12.520Z Has data issue: false hasContentIssue false
  • English
  • Français

An Integrated Analysis of the Safety and Tolerability of Desvenlafaxine Compared with Placebo in the Treatment of Major Depressive Disorder

Published online by Cambridge University Press:  07 November 2014

Anita H. Clayton ,
Susan G. Kornstein ,
Gregory Rosas ,
Christine Guico-Pabia  and
Karen A. Tourian
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction: The safety and tolerability profiles of antidepressants can often influence the treatment choices of clinicians treating major depressive disorder. The purpose of this investigation was to characterize the safety and tolerability of desvenlafaxine (administered as desvenlafaxine succinate) in treating depression.

Methods: An integrated analysis of all short-term, randomized, double-blind, placebo-controlled registration studies for major depressive disorder (four flexible-dose and five fixed-dose studies) was performed. Adult outpatients with major depressive disorder received desvenla-faxine doses ranging from 50–400 mg/day or placebo for 8 weeks. Treatment-emergent adverse events, laboratory values, vital signs, and discontinuation symptoms were evaluated. In the subset of fixed-dose studies, dose-related effects were analyzed.

Results: In the overall population (placebo: n=1,116; desvenlafaxine: n=1,834), adverse events resulted in discontinuations in 3% of placebo-treated patients and 12% of desvenla-faxine-treated patients; in the subset of fixed-dose studies, the rates were 4% with placebo and increased with desvenlafaxine dose (50 mg/ day: 4%; 400 mg/day: 18%). The most common treatment-emergent adverse event was transient nausea that was generally mild to moderate. The most common sexual dysfunction associated with desvenlafaxine treatment was erectile dysfunction in men (7% vs 1% with placebo) and anorgasmia in women (1% and 0%). One desvenlafaxine-treated patient died of a completed suicide; there were four suicide attempts (three desvenlafaxine, one placebo) and eight cases of suicidal ideation (five desvenlafaxine, three placebo) during the on-therapy period. Small but statistically significant changes in mean blood pressure occurred at all desvenlafaxine doses; clinically meaningful changes were observed in 1% of placebo-treated patients and 2% of desvenlafaxine-treated patients. Desvenlafaxine was associated with small but statistically significant mean changes in laboratory assessments, particularly lipid and liver enzyme elevations, and electrocardiograms; few cases of these changes were clinically relevant.

Conclusion: Desvenlafaxine in the treatment of major depressive disorder exhibited a safety and tolerability profile generally consistent with the serotonin-norepinephrine reuptake inhibitor class. The most common adverse event was transient nausea. At the recommended therapeutic dose of 50 mg/day, discontinuation due to adverse events was similar to placebo.

Type
Original Research
Information
CNS Spectrums , Volume 14 , Issue 4 , April 2009 , pp. 183 - 195
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Deecher, DC, Beyer, CE, Johnston, G, et al.Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318:657–665.CrossRefGoogle ScholarPubMed
2.DeMartinis, NA, Yeung, PP, Entsuah, R, Manley, AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68:677–688.CrossRefGoogle ScholarPubMed
3.Septien-Velez, L, Pitrosky, B, Padmanabhan, SK, Germain, J-M, Tourian, KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22:338–347.CrossRefGoogle ScholarPubMed
4.Boyer, P, Montgomery, S, Lepola, U, et al.Efficacy, safety, and tolerability of fixeddose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23:243–253.Google Scholar
5.Liebowitz, M, Manley, AL, Padmanabhan, SK, Ganguly, R, Tummala, R, Tourian, KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24:1877–1890.Google Scholar
6.Thase, ME, Kornstein, SG, Germain, J-M, Jiang, Q, Guico-Pabia, C, Ninan, PT. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009;14;144–154.CrossRefGoogle ScholarPubMed
7.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
8.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.Google Scholar
9.Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.Google Scholar
10.Lieberman, DZ, Montgomery, SA, Tourian, KAet al.A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008;23:188–197.Google Scholar
11.Rosenbaum, JF, Fava, M, Hoog, SL, Ascroft, RC, Krebs, WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77–87.CrossRefGoogle ScholarPubMed
12.Montgomery, S, Fava, M, Tourian, KA, Padmanabhan, SK, Guico-Pabia, C. Discontinuation symptoms and taper/post-study-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Poster presented at: American Psychiatric Association Annual Meeting, May 3-8, 2008, Washington, DC.Google Scholar
13. Advice for the Pharmaceutical Industry in Exploring their Placebo-Controlled Clinical Trials Databases for Suicidality and Preparing Datasets for Analysis by FDA. US Food and Drug Administration, Division of Neuropharmacological Drug Products (DNDP); 2005.Google Scholar
14.Jick, H, Kaye, JA, Jick, SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292(3):338–343.Google Scholar
15.McKenzie, MS, McFarland, BH. Trends in antidepressant overdoses. Pharmacoepidemiol Drug Saf. 2007;16:513–523.Google Scholar
16.Fava, M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry. 2006;67(suppl 4):14–21.Google ScholarPubMed
17.Rickels, K, Montgomery, SA, Tourian, KA, Guelfi, JD, Pitrosky, B, Padmanabhan, SK. A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of desvenlafaxine succinate for prevention of depressive relapse in adult outpatients with major depressive disorder. Poster presented at: Annual Meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, CA.Google Scholar
18.Hudson, JI, Wohlreich, MM, Kajdasz, DK, Mallinckrodt, CH, Watkin, JG, Martynov, DV. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol. 2005;20:327–341.CrossRefGoogle ScholarPubMed
19.Thase, ME, Tran, PV, Wiltse, C, Pangallo, BA, Mallinckrodt, C, Detke, MJ. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005;25:132–140.CrossRefGoogle ScholarPubMed
20.Thase, ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59:502–508.Google Scholar
21.Paul, J, Behrle, JA, Richards, LS, Menton, R, Nichols, Al, Posener, JA. Effect of desvenlafaxine succinate on QT interval in healthy adult female subjects: a double-blind, placeboand moxifloxacin-controlled crossover study. Poster presented at: Annual Meeting of the American Psychiatry Association; May 20-25, 2006; Toronto, Canada.Google Scholar
22.Gregorian, RS, Golden, KA, Bahce, A, Goodman, C, Kwong, WJ, Khan, ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother. 2002;36:1577–1589.Google Scholar
23.Liebowitz, M, Yeung, PP, Entsuah, R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68:1663–1672.Google Scholar
24.Feiger, AD, Tourian, K, Rosas, G, Padmanabhan, K. A placebo-controlled efficacy and safety study of a flexible dose of desvenlafaxine in outpatients with major depressive disorder. CNS Spectr. 2009;14:41–50.Google Scholar